Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms

Authors:

Abstract
Herein, we describe the design, synthesis, and structure-activity relationships of a series of unique 4-(1H-pyrazol-4-yl)-pyrimidin-2-amine derivatives that selectively inhibit JAK2 and FLT3 kinases. These screening cascades revealed that 18e was a preferred compound, with IC50 values of 0.7 nM and 4 nM for JAK2 and FLT3, respectively. Moreover, 18e was a potent JAK2 inhibitor with 37-fold and 56-fold selectivity over JAK1 and JAK3, respectively, and possessed an excellent selectivity profile over the other 100 representative kinases. In a series of cytokine-stimulated cell-based assays, 18e exhibited a higher JAK2 selectivity than other JAK isoforms. The oral administration of 18e at 60 mg/kg could significantly inhibit tumor growth, with a tumor growth inhibitory rate of 93% and 85% in MV4-11 and SET-2 xenograft models, respectively. Additionally, 18e showed an excellent bioavailability (F = 58%), a suitable half-life time (T1/2 = 4.1 h), a satisfactory metabolic stability and a weak CYP3A4 inhibitory activity, suggesting that 18e might be a potential drug candidate for JAK2-driven myeloproliferative neoplasms and FLT3-ITD driven acute myelogenous leukemia.
Funding Information
  • National Natural Science Foundation of China (81703344, 81673289)
  • 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University